European Pharmaceutical Review: SynBio: unlocking the commercial potential of a new bioscience industry

Magda Papadaki, Head of Manufacturing Innovation for ABPI and an alumna of Cambridge Judge Business School (MPhil in Bioscience Enterprise 2012), writes about the implications of synthetic biology for the pharmaceutical industry. “Ultimately, the UK needs a joined-up system with the right fiscal environment, support from highly skilled scientists, multi-stakeholder innovation including with the NHS, clear regulatory guidelines and education which lay the groundwork to a positive uptake environment, and a new generation of innovation leaders, to deliver the successes that SynBio promises.”

Read the full article [europeanpharmaceuticalreview.com]